

# **Investigation into Peroxiredoxin and interactions in the Peroxiredoxin peroxide scavenging system**

Submitted by

**Paul Brian Charles James**

to the University of Exeter as a thesis for the degree of Doctor of Philosophy in  
Biological Sciences

(September 2010)

This thesis is available for Library use on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.

I certify that all material in this thesis which is not my own work has been identified and that no material has previously been submitted and approved for the award of a degree by this or any other University.

Paul James

## Abstract

Peroxiredoxins are a family of multifunctional enzymes that are able to protect the cell against oxidative stress. Peroxiredoxins form part of a recently discovered peroxide scavenging system along with thioredoxin, thioredoxin reductase and sulfiredoxin.

This study describes the purification of a recombinant human peroxiredoxin II from human erythrocytes. The original recombinant clone contained a point mutation at the fourth residue from glycine to valine and a number of problems were encountered with aggregation during purification. Reverting back to the original amino acid sequence allowed the protein to be purified and concentrated without aggregation, as well as leading to over-expression in the same oligomeric state as the native sample from blood.

This study also describes the over-expression and purification of the human peroxiredoxin II protein in the intermolecular disulfide form as well as the subsequent crystallisation and X-ray diffraction studies. The crystal structure for this form of the protein was obtained to 3.3 Å resolution revealing the peroxiredoxin to be in the decameric form. In addition conformational changes in the protein that are necessary for formation of the intermolecular disulfide between the peroxidatic (Cys52) and resolving cysteine (Cys172) have been observed. The structure also revealed that these movements did not interfere with the dimer:dimer interface as had been previously suggested. This then allows the disulfide to be seen within the decameric form of peroxiredoxin.

The production of covalent complexes formed between peroxiredoxin and sulfiredoxin, and peroxiredoxin and thioredoxin was also investigated. Complexes were stabilised by using DTNB to form a covalent bond between specific cysteine residues. The complex binding results from size exclusion chromatography showed that decameric peroxiredoxin bound to sulfiredoxin in a 1:5 ratio and decameric peroxiredoxin bound to thioredoxin in a 1:10 ratio.

Cloning, over-expression and purification of the selenocysteine containing enzyme thioredoxin reductase was achieved. A minimal selenocysteine insertion sequence was added to the 3' end of the DNA sequence to drive selenocysteine insertion in place of the typical stop UGA codon. The activity of

this protein was found to be low but was greatly increased when co-expressed with a plasmid containing the *se/A*, *se/B* and *se/C* genes. Although the activity of this co-expressed thioredoxin reductase was ~20% of the native enzyme activity, it was comparable to the activity of other recombinant forms of the enzyme.

These studies report the purification of all of the proteins necessary to reform the peroxiredoxin system and allow the production of a working assay for peroxiredoxin activity. Together with the first report for a structure of a decameric disulfide form of human peroxiredoxin II a greater insight into the peroxiredoxin system has been obtained.

## **Acknowledgements**

I would like to thank Prof. Jenny Littlechild for all her support and encouragement throughout this PhD and my scientific career to date. I am very grateful to Dr. Michail Isupov for his help and advice with the crystallography performed in this work. I am also very grateful to Dr Kirsty Line for her continued support and patience throughout this project. I would also like to thank Dr. Andrew Shaw and Dr Robert Parker for their help with the SPR. I would also like to thank Prof. Willison and Heather Rada for giving me the chance to look at the interaction with PDCL3.

I would like to thank everybody from the Biocatalysis Centre both past and present that have helped me throughout this project. Especially Kirsty, Carrie, Anne Marie and Chris who were always available for scientific discussion or an extended tea into lunch break.

I would like to thank my family for their continued love and support. Finally I would like to thank Lizzy and Hannah for all their support and for always being on hand for a glass of wine, or a gin.

## Abbreviations

3D	3-dimensional
APS	Ammonium persulfate
ATP	Adenosine triphosphate
BAM	Benzamidine
BASI	barley $\alpha$ -amylase/subtilisin inhibitor
BE	Adherent human colon carcinoma cells
CCP4	Collaborative computational project, number 4
DNA	Deoxyribonucleic acid
DTNB	5,5'-dithiobis-(2-nitrobenzoic acid)
DTT	Dithiothreitol
EC	Enzyme commission
EDC	1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide
EDTA	Ethylenediaminetetraacetic acid
EM	Electron microscopy
ESI-MS	Electrospray ionization mass spectrometry
FAD	Flavin adenine dinucleotide
FFQ	Fast flow Q Sepharose
GF	Gel filtration
HEPES	N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
His-tag	Poly histidine tag
IPTG	Isopropyl-1-thio- $\beta$ -D-galactopyranoside
LB	Luria-Bertani
LDAO	Lauryldimethylamineoxide
MAD	Multiple-wavelength anomalous diffraction
MWCO	Molecular weight cut off
NADPH	Nicotinamide adenine dinucleotide phosphate
NHS	N-hydrocysulfosuccinimide
OD	Optical density
PAGE	Polyacrylamide gel electrophoresis
PCR	Polymerase chain reaction
PDB	Protein data bank
PEG	Polyethylene glycol

PLP2	Yeast phosducin-like protein 2
PMSF	Phenylmethanesulfonylfluoride
Prx	Peroxiredoxin
RMS	Root mean square
ROS	Reactive oxygen species
SAD	Single-wavelength anomalous diffraction
SAXS	Small angle X-ray scattering
SDS	Sodium dodecyl sulfate
SECIS	Selenocysteine insertion sequence
SLIM	Site-directed ligase independent mutagenesis
SOD	Superoxide dismutase
SPR	Surface plasmon resonance
Srx	Sulfiredoxin
TCEP	Tris(2-carboxyethyl)phosphine
TEMED	N,N,N',N'-Tetramethyl-1-,2-diaminomethane
T <sub>M</sub>	Melting temperature
TNB	5-thiobis-(2-nitrobenzoic acid)
Tris-HCl	Tris (hydroxymethyl) aminomethane
Trx	Thioredoxin
TrxR	Thioredoxin reductase
UV	Ultraviolet

# Table of Contents

Abstract.....	2
Acknowledgements.....	4
Abbreviations.....	5
Table of Contents.....	7
List of Figures.....	17
List of Tables.....	22
List of Equations.....	22
1. Introduction.....	23
1.1. Reactive oxygen species.....	23
1.1.1. Superoxide anion.....	23
1.1.2. Hydrogen peroxide.....	24
1.1.3. Hydrogen peroxide redox signaling.....	24
1.1.4. The hydroxyl radical.....	25
1.1.5. Sites of production of reactive oxygen species.....	25
1.1.6. The human erythrocyte.....	25
1.2. Antioxidant enzymes.....	26
1.3. Oxidative stress.....	27
1.4. The biological redox chemistry of cysteine.....	27
1.4.1. Reaction of thiol with hydrogen peroxide.....	29
1.4.2. Forming the disulfide state.....	29
1.4.3. Forming the sulfinic acid state.....	29
1.5. Peroxiredoxin.....	30
1.5.1. Peroxiredoxin 2 from human erythrocytes.....	31
1.5.1.1. The structure of hPrxII.....	32
1.5.1.2. The structure of the hPrxII active site.....	34
1.5.1.3. The hPrxII catalytic cycle.....	36
1.5.1.4. The hPrxII mechanism.....	37

1.5.1.5.	The hyper-oxidation of Peroxiredoxin.....	37
1.5.1.6.	Oligomerisation of peroxiredoxin II.....	38
1.5.1.7.	Peroxiredoxin chaperone activity .....	40
1.5.1.8.	Peroxiredoxin cell signalling activity .....	40
1.6.	Sulfiredoxin .....	41
1.6.1.	Human sulfiredoxin.....	41
1.6.1.1.	Structure of hSrx .....	41
1.6.1.2.	hSrx mechanism .....	42
1.6.2.	The peroxiredoxin – sulfiredoxin interaction .....	43
1.7.	Thioredoxin .....	47
1.7.1.	Human thioredoxin.....	48
1.7.1.1.	hTrx mechanism.....	48
1.7.1.2.	hTrx structure .....	49
1.7.1.2.1.	Reduced form of hTrx.....	50
1.7.1.2.2.	Oxidized hTrx .....	52
1.7.1.2.3.	The hTrx dimer.....	53
1.7.1.3.	hTrx interaction with hPrxII.....	54
1.8.	Thioredoxin reductase.....	54
1.8.1.	Human thioredoxin reductase 1 .....	55
1.8.1.1.	Mechanism of hTrxR1 .....	55
1.8.1.2.	Structure of hTrxR1 .....	56
1.9.	Reconstitution of the Peroxiredoxin system .....	58
1.10.	Aims of the project .....	58
2.	Cloning, expression and purification of Human Peroxiredoxin II from red blood cells and the effect of a fourth residue mutation .....	60
2.1.	Introduction .....	60
2.2.	Materials and Methods.....	61
2.2.1.	Cloning of <i>hPrxII</i> .....	61



2.2.2.	Transformation of hPrxII into an expression cell line .....	63
2.2.3.	Expression of recombinant hPrxII .....	64
2.2.4.	Purification of Recombinant hPrxII.....	64
2.2.4.1.	Cell lysis .....	64
2.2.4.2.	Purification buffers .....	64
2.2.4.3.	Nickel affinity chromatography .....	64
2.2.4.4.	Gel filtration chromatography .....	65
2.2.4.5.	Protein concentration .....	65
2.2.4.6.	SDS-PAGE.....	66
2.2.4.6.1.	Stock solutions .....	66
2.2.4.6.2.	Preparation of gels .....	66
2.2.4.6.3.	Sample preparation .....	67
2.2.4.6.4.	Sample preparation using non-reducing buffer.....	67
2.2.4.6.5.	SDS-PAGE running.....	67
2.2.4.6.6.	Gel staining procedure .....	68
2.2.4.7.	Protein concentration determination using A280.....	68
2.2.5.	Purification of native hPrxII .....	68
2.2.5.1.	Haemolysis and purification buffers .....	68
2.2.5.2.	Preparation and haemolysis of erythrocytes .....	69
2.2.5.3.	Ion exchange chromatography of native hPrxII .....	69
2.2.5.4.	Size exclusion chromatography of native hPrxII.....	69
2.3.	Results .....	70
2.3.1.	Cloning of <i>hPrxII</i> gene .....	70
2.3.2.	Expression of recombinant hPrxII .....	70
2.3.3.	Purification of recombinant hPrxII .....	71
2.3.3.1.	Nickel Affinity Chromatography .....	71
2.3.3.2.	Gel filtration chromatography .....	73

2.3.3.3.	Overview of purification of hPrxII (4Gcorrect) and hPrxII (4Vincorrect).....	74
2.3.4.	Purification of native hPrxII .....	75
2.3.4.1.	Ion exchange chromatography of native hPrxII .....	75
2.3.4.2.	Gel filtration chromatography of native hPrxII .....	76
2.3.4.3.	Overview of purification of native hPrxII .....	78
2.4.	Discussion.....	79
3.	Crystallization and structure determination of the disulfide state of hPrxII .	84
3.1.	Introduction .....	84
3.1.1.	hPrxII disulfide state .....	84
3.1.2.	Producing the protein in the disulfide state .....	84
3.1.3.	Protein crystallography .....	85
3.1.4.	X-ray crystallography .....	87
3.2.	Materials and methods.....	92
3.2.1.	Expression of protein in the disulfide state .....	92
3.2.2.	Protein purification of hPrxII(S-S) .....	92
3.2.2.1.	Cell lysis.....	92
3.2.2.2.	Purification buffers .....	92
3.2.2.3.	Nickel affinity and gel filtration chromatography.....	92
3.2.3.	Western blot analysis.....	93
3.2.4.	Crystallization of hPrxII(S-S).....	94
3.2.4.1.	Preparation of proteins.....	94
3.2.4.2.	Initial crystal trials.....	94
3.2.4.3.	Optimization of crystal trails .....	94
3.2.4.4.	Preparing crystals for data collection .....	94
3.2.5.	X-Ray data collection.....	95
3.2.6.	Structure Determination.....	95
3.2.6.1.	Data processing .....	95

3.2.6.2.	Phase determination .....	95
3.2.6.3.	Model building and refinement .....	95
3.2.6.4.	Structure validation .....	95
3.3.	Results .....	95
3.3.1.	Expression of the protein in the disulfide state .....	95
3.3.2.	Protein purification of hPrxII(S-S) .....	96
3.3.2.1.	Nickel affinity and gel filtration chromatography of hPrxII(S-S) .. .....	96
3.3.3.	Crystallization of hPrxII(S-S).....	100
3.3.4.	Structure determination .....	100
3.3.4.1.	X-ray data collection.....	100
3.3.4.2.	Structure solution .....	101
3.3.4.3.	Model building and validation .....	102
3.4.	Discussion.....	104
3.4.1.	Expression of the protein in the disulfide state .....	104
3.4.2.	Crystal structure of hPrxII(S-S).....	104
3.4.2.1.	Monomer unit .....	104
3.4.2.2.	Dimer structure.....	105
3.4.2.3.	Decameric structure .....	106
3.4.2.4.	The active site .....	107
3.4.2.5.	Structural comparison between hPrxII hyper-oxidized/thiol and hPrxII(S-S) crystal structure.....	108
4.	Study of the complexes formed between hPrxII and the proteins it interacts with in the Prx antioxidant system. ....	113
4.1.	Introduction .....	113
4.1.1.	The interaction between hPrxII and Srx.....	113
4.1.2.	The interaction between hPrxII and Trx.....	114
4.1.3.	Site-directed ligase independent mutagenesis (SLIM) of Srx to ET- Srx .....	114

4.1.4.	Site directed mutagenesis .....	115
4.1.4.1.	Site directed mutagenesis of hPrxII to mPrxII .....	115
4.1.4.2.	Site directed mutagenesis of Trx to mTrx.....	115
4.1.5.	Chemical conjugation of the proteins.....	116
4.1.5.1.	Chemical conjugation of mPrxII to ET-Srx.....	116
4.1.5.2.	Chemical conjugation of mPrxII and Trx .....	116
4.1.6.	Potential interaction with PDCL3 .....	117
4.1.7.	Surface plasmon resonance .....	117
4.2.	Materials and Methods .....	120
4.2.1.	Cloning of <i>ET-Srx</i> .....	120
4.2.1.1.	Primer design .....	120
4.2.1.2.	SLIM PCR amplification .....	121
4.2.1.3.	SLIM hybridization.....	121
4.2.2.	Site directed mutagenesis of hPrxII to mPrxII and Trx to mTrx...	121
4.2.2.1.	Primer design .....	121
4.2.2.2.	Site directed mutagenesis .....	122
4.2.3.	Expression of ET-Srx.....	122
4.2.4.	Expression of mTrx.....	123
4.2.5.	Expression of mPrxII.....	123
4.2.6.	Protein purification of ET-Srx and mTrx.....	123
4.2.6.1.	Cell lysis .....	123
4.2.6.2.	Purification buffers .....	123
4.2.6.3.	Nickel affinity chromatography .....	123
4.2.6.4.	Gel filtration chromatography .....	123
4.2.7.	Protein purification of mPrxII.....	124
4.2.7.1.	Cell lysis .....	124
4.2.7.2.	Purification buffers .....	124
4.2.7.3.	Nickel affinity and gel filtration chromatography.....	124

4.2.8.	Conjugation of the mPrxII to both mTrx and ET-Srx .....	124
4.2.9.	Crystallization of both complexes .....	125
4.2.10.	Interaction with PDCL3.....	125
4.2.10.1.	Probing the interaction via native gel electrophoresis .....	125
4.2.10.2.	Native SDS-PAGE .....	125
4.2.10.3.	Probing the interaction via sucrose gradients.....	126
4.2.10.4.	Identification of potential binding partners for hPrxII .....	126
4.2.10.4.1.	Confirmation of binding to a Zymo His-Affinity column ...	126
4.2.10.4.2.	Identification of binding partners using the Zymo His-Affinity column .....	127
4.2.11.	Surface plasmon resonance assay .....	127
4.2.11.1.	Interactions between hyperoxidised hPrxII and Srx .....	128
4.2.11.2.	Interaction between disulfide hPrxII and Trx.....	128
4.3.	Results .....	128
4.3.1.	Cloning of <i>ET-Srx</i> .....	128
4.3.2.	Site directed mutagenesis of hPrxII to mPrxII .....	129
4.3.3.	Expression of ET-Srx.....	129
4.3.4.	Expression of mTrx.....	129
4.3.5.	Expression of mPrxII.....	129
4.3.6.	Purification of ET-Srx and mTrx.....	130
4.3.6.1.	ET-Srx nickel affinity chromatography.....	130
4.3.6.2.	mTrx nickel affinity chromatography.....	131
4.3.6.3.	ET-Srx gel filtration chromatography.....	133
4.3.6.4.	mTrx gel filtration chromatography.....	135
4.3.7.	Purification of mPrxII.....	136
4.3.7.1.	Nickel affinity and gel filtration chromatography.....	136
4.3.8.	Conjugation of mPrxII to ET-Srx .....	139
4.3.9.	Conjugation of mPrxII to mTrx .....	141

4.3.10.	Interaction with PDCL3.....	143
4.3.10.1.	Probing the interaction via native gel electrophoresis .....	143
4.3.10.2.	Probing the interaction via sucrose gradients.....	144
4.3.10.3.	Identification of potential binding partners for hPrxII .....	145
4.3.10.3.1.	Confirmation of binding to a Zymo His-Affinity column ...	145
4.3.10.3.2.	Identification of binding partners using the Zymo His-Affinity column .....	146
4.3.11.	Surface plasmon resonance assay results .....	147
4.4.	Discussion.....	148
4.4.1.	The mPrxII-ET-Srx Complex.....	148
4.4.2.	The mPrxII-mTrx Complex.....	151
4.4.3.	Interaction with PDCL3 .....	154
4.4.4.	Surface plasmon resonance .....	155
4.4.4.1.	Interactions between hyperoxidised hPrxII and Srx .....	155
5.	The cloning and over-expression of an active human thioredoxin reductase. ....	157
5.1.	Introduction .....	157
5.1.1.	Thioredoxin reductase .....	157
5.1.2.	Selenocysteine and selenocysteine incorporation .....	157
5.1.2.1.	Selenocysteine insertion sequence.....	157
5.1.2.2.	Co-expression with the <i>selA</i> , <i>selB</i> and <i>selC</i> genes and the use of a double stop codon .....	158
5.2.	Materials and Methods.....	159
5.2.1.	Cloning of <i>hTrxR1</i> .....	159
5.2.1.1.	Primer sequences .....	160
5.2.1.2.	PCR of <i>hTrxR1</i> .....	160
5.2.1.3.	T4 DNA polymerase treatment of the <i>hTrxR1</i> insert .....	161
5.2.1.4.	Annealing the vector and prepared insert .....	161
5.2.2.	Expression of recombinant hTrxR1.....	161

5.2.2.1.	Co-expression with pSUABC .....	162
5.2.3.	Purification of recombinant TrxR1.....	163
5.2.3.1.	Purification buffers .....	163
5.2.3.2.	Nickel affinity and gel chromatography .....	163
5.2.4.	TrxR1 DTNB assay .....	163
5.2.5.	Reconstitution of the PrxII pathway .....	163
5.3.	Results .....	164
5.3.1.	Cloning of <i>TrxR1</i> .....	164
5.3.2.	Expression of recombinant TrxR1.....	164
5.3.3.	Purification of recombinant TrxR1.....	165
5.3.3.1.	Nickel affinity and gel filtration chromatography.....	165
5.3.4.	TrxR1 DTNB activity assay .....	167
5.3.5.	Reconstitution of the PrxII pathway .....	168
5.4.	Discussion.....	168
5.4.1.	Activity of hTrxR1.....	168
5.4.2.	Reconstitution of the PrxII pathway .....	169
6.	Summary and further work.....	171
6.1.	Summary.....	171
6.2.	Further work .....	173
7.	Appendix.....	176
7.1.	Superdex 200 gel filtration column calibration.....	176
7.2.	BioRad Precision Plus Protein Standard 15 – 250 kDa.....	176
7.3.	Hyperladder I (BIOLINE) .....	177
7.4.	MDL 1 & 2 Crystal screen (Molecular Dimensions Laboratories) .....	178
7.4.1.	MD1-01 .....	178
7.4.2.	MD1-02.....	179
7.5.	Sigma crystal screens .....	180
7.5.1.	Sigma 8007 Crystal Screen (Sigma).....	180

7.5.2. Sigma 70437 Crystal Screen (Sigma).....	181
7.6. JCSG Crystal Screen (Molecular Dimensions Laboratories).....	182
7.6.1. Box 1 .....	182
7.6.2. Box 2 .....	183
7.7. Ramachandran plot for the hPrxII(S-S) structure .....	184
7.8. ET-Srx mutation .....	185
7.8.1. DNA sequence.....	185
7.8.2. Protein sequence.....	185
7.9. mPrxII mutation .....	185
7.9.1. DNA sequence (Mutation in bold).....	185
Protein sequence (Mutation in bold) .....	185
7.10. Spectra™ multicolour broad range protein ladder (Fermentas) .....	186
7.11. hTrxR1 .....	186
7.11.1. DNA sequence (SECIS in bold).....	186
7.11.2. Protein sequence .....	187
7.12. Sigma SDS 7 molecular weight marker .....	187
Reference List .....	188



## List of Figures

<b>1.1</b>	The chemical structure of the amino acid cysteine in the thiol, sulfenic acid and sulfinic acid form	<b>28</b>
<b>1.2</b>	Cartoon diagram of the hPrxII monomer	<b>32</b>
<b>1.3</b>	Cartoon diagram of the hPrxII dimer	<b>33</b>
<b>1.4</b>	Cartoon diagram of the hPrxII decamer	<b>34</b>
<b>1.5</b>	Ribbon and stick diagram of the hPrxII active site	<b>35</b>
<b>1.6</b>	The hPrxII catalytic cycle	<b>36</b>
<b>1.7</b>	The mechanism of the 1 <sup>st</sup> step of the peroxidation reaction of hPrxII	<b>37</b>
<b>1.8</b>	Cartoon representation of the GGLG and YF structural motifs	<b>38</b>
<b>1.9</b>	Cartoon diagram of the hSrx structure	<b>41</b>
<b>1.10</b>	Mechanism of the reduction of the sulfinic acid Cys <sub>P</sub> by hSrx	<b>43</b>
<b>1.11</b>	Cartoon and stick diagram of the disulfide bond between hPrxI and ET-Srx	<b>44</b>
<b>1.12</b>	Cartoon diagram of the hPrxI-ET-Srx complex	<b>45</b>
<b>1.13</b>	Cartoon diagram of the hPrxI-ET-Srx complex with ATP and Mg <sup>2+</sup>	<b>46</b>
<b>1.14</b>	Cartoon diagram of the hPrxI-ET-Srx interaction site	<b>47</b>
<b>1.15</b>	The catalytic cycle of hTrx	<b>48</b>
<b>1.16</b>	The mechanism for the reduction of a target protein by thioredoxin	<b>49</b>
<b>1.17</b>	Cartoon diagram of the hTrx reduced structure	<b>50</b>
<b>1.18</b>	Cartoon diagram of the two redox active cysteine residues in the reduced form of hTrx	<b>51</b>
<b>1.19</b>	Surface diagram of the redox active cysteine residues in the reduced form of hTrx	<b>52</b>
<b>1.20</b>	Ribbon and stick diagram comparison of the position of the active site cysteine residues in both the oxidized and reduced forms of hTrx	<b>53</b>

<b>1.21</b>	The proposed mechanism of Trx reduction by TrxR1	<b>56</b>
<b>1.22</b>	Cartoon diagram of the structure of TrxR1	<b>57</b>
<b>1.23</b>	Cartoon diagram of the TrxR1 active site in the oxidized and reduced form	<b>58</b>
<b>2.1</b>	Comparison of the protein sequences for hPrxII (4Gcorrect) and hPrxII (4Vincorrect)	<b>60</b>
<b>2.2</b>	Comparison of the first 200 bp of the DNA sequences for hPrxII (4Gcorrect) and hPrxII (4Vincorrect)	<b>61</b>
<b>2.3</b>	The strategy for the cloning of <i>hPrxII</i>	<b>63</b>
<b>2.4</b>	Agarose gel of <i>hPrxII</i> PCR	<b>70</b>
<b>2.5</b>	Elution profile from nickel affinity chromatography for hPrxII (4Gcorrect) and hPrxII (4Vincorrect).	<b>71</b>
<b>2.6</b>	SDS-PAGE of hPrxII (4Vincorrect) from nickel affinity chromatography	<b>72</b>
<b>2.7</b>	SDS-PAGE of hPrxII (4Gcorrect) from nickel affinity chromatography	<b>72</b>
<b>2.8</b>	Elution profile from gel filtration chromatography for hPrxII (4Gcorrect), hPrxII (4Vincorrect) and native hPrxII	<b>73</b>
<b>2.9</b>	SDS-PAGE of hPrxII (4Gcorrect), hPrxII (4Vincorrect) and native hPrxII from gel filtration chromatography	<b>74</b>
<b>2.10</b>	Elution profile from ion exchange chromatography for native hPrxII	<b>75</b>
<b>2.11</b>	SDS-PAGE of native hPrxII from ion exchange chromatography	<b>76</b>
<b>2.12</b>	Elution profile from gel filtration chromatography for native hPrxII	<b>77</b>
<b>2.13</b>	SDS-PAGE of native hPrxII from gel filtration chromatography	<b>78</b>
<b>2.14</b>	Structural comparison between glycine and valine	<b>79</b>
<b>2.15</b>	Cartoon diagram of the glycine residue position in hPrxII 4Gcorrect	<b>80</b>
<b>2.16</b>	Cartoon diagram of the glycine residue position in hPrxII 4Vincorrect	<b>80</b>

<b>2.17</b>	Cartoon diagram of the dimer:dimer interface	<b>81</b>
<b>2.18</b>	Cartoon diagram of the potential movement caused by the mutation of glycine to valine	<b>82</b>
<b>3.1</b>	The structure of the thiol oxidizing agent diamide.	<b>85</b>
<b>3.2</b>	Protein phase diagram	<b>86</b>
<b>3.3</b>	Microbatch crystallization experiments	<b>86</b>
<b>3.4</b>	Conditions that satisfy Bragg's law	<b>88</b>
<b>3.5</b>	Ewald's sphere	<b>89</b>
<b>3.6</b>	Elution profile from nickel affinity chromatography for hPrxII(S-S)	<b>97</b>
<b>3.7</b>	Elution profile from gel filtration chromatography for hPrxII(S-S)	<b>98</b>
<b>3.8</b>	SDS-PAGE of hPrxII(S-S) from gel filtration chromatography	<b>99</b>
<b>3.9</b>	Western blot analysis of hPrxII(S-S)	<b>99</b>
<b>3.10</b>	hPrxII(S-S) crystals	<b>100</b>
<b>3.11</b>	Cartoon diagram of the hPrxII(S-S) monomer	<b>105</b>
<b>3.12</b>	Cartoon diagram of the hPrxII(S-S) dimer	<b>106</b>
<b>3.13</b>	Cartoon diagram of the hPrxII(S-S) decamer	<b>107</b>
<b>3.14</b>	The $2F_o-F_c$ electron density map and The $F_o-F_c$ omit map of the disulfide in hPrxII(S-S)	<b>108</b>
<b>3.15</b>	Cartoon diagram of the hPrxII(S-S) active site	<b>108</b>
<b>3.16</b>	Ribbon diagram comparing the hPrxII(S-S) & hPrxII monomeric structure	<b>109</b>
<b>3.17</b>	Ribbon diagram comparing the hPrxII(S-S) & hPrxII redox cysteine positions	<b>110</b>
<b>3.18</b>	Ribbon diagram comparing the hPrxII(S-S) & hPrxII active site residues	<b>111</b>
<b>3.19</b>	Ribbon diagram comparing the hPrxII(S-S) & hPrxII dimer:dimer interface	<b>112</b>
<b>4.1</b>	The SLIM method for the production of ET-Srx	<b>115</b>

<b>4.2</b>	The mechanism of conjugation between mPrxII and ET-Srx using DTNB	<b>116</b>
<b>4.3</b>	The mechanism of conjugation between mPrxII and mTrx using DTNB	<b>117</b>
<b>4.4</b>	The set up of the SPR assay	<b>118</b>
<b>4.5</b>	The 3 steps for ligand immobilization to the surface of a carboxylic acid coated gold chip.	<b>119</b>
<b>4.6</b>	A sensogram showing the steps of an SPR assay	<b>120</b>
<b>4.7</b>	Elution profile from nickel affinity chromatography for ET-Srx	<b>130</b>
<b>4.8</b>	SDS-PAGE of ET-Srx from nickel affinity chromatography	<b>131</b>
<b>4.9</b>	Elution profile from nickel affinity chromatography for mTrx	<b>132</b>
<b>4.10</b>	SDS-PAGE of mTrx from nickel affinity chromatography	<b>133</b>
<b>4.11</b>	Elution profile from gel filtration chromatography for ET-Srx	<b>134</b>
<b>4.12</b>	SDS-PAGE of ET-Srx from gel filtration chromatography	<b>134</b>
<b>4.13</b>	Elution profile from gel filtration chromatography for mTrx	<b>135</b>
<b>4.14</b>	SDS-PAGE of mTrx from gel filtration chromatography	<b>136</b>
<b>4.15</b>	Elution profile from nickel affinity chromatography for mPrxII	<b>137</b>
<b>4.16</b>	SDS-PAGE of mPrxII from nickel affinity chromatography	<b>137</b>
<b>4.17</b>	Elution profile from gel filtration chromatography for mPrxII	<b>138</b>
<b>4.18</b>	SDS-PAGE of mPrxII from gel filtration chromatography	<b>138</b>
<b>4.19</b>	Elution profile from gel filtration chromatography for mPrxII-ET-Srx complex	<b>139</b>
<b>4.20</b>	SDS-PAGE of mPrxII-ET-Srx complex from gel filtration chromatography	<b>140</b>
<b>4.21</b>	Elution profile from gel filtration chromatography for mPrxII-mTrx complex	<b>141</b>
<b>4.22</b>	SDS-PAGE of mPrxII-mTrx complex from gel filtration chromatography	<b>142</b>
<b>4.23</b>	Native-PAGE analysis of the complex between PDCI3 and	<b>143</b>

	hPrxII	
<b>4.24</b>	Fluorescence analysis of the complex between PDCL3 and hPrxII	<b>144</b>
<b>4.25</b>	SDS-PAGE analysis of hPrxII interacting with PDCL3 on a sucrose gradient	<b>145</b>
<b>4.26</b>	Fluorescence image hPrxII interacting with PDCL3 <sup>*568</sup> on a sucrose gradient	<b>145</b>
<b>4.27</b>	SDS-PAGE of hPrxII binding to the Zymo His-Affinity column	<b>146</b>
<b>4.28</b>	SDS-PAGE of hPrxII pull down from the BE cell lysate	<b>147</b>
<b>4.29</b>	Typical sensogram for the immobilization of the ligand to the chip surface	<b>148</b>
<b>4.30</b>	Typical sensogram showing non-specific binding in the SPR assay	<b>148</b>
<b>4.31</b>	Surface view of a hPrxII-Srx model	<b>150</b>
<b>4.32</b>	Surface view of the hPrxI-Et-Srx complex modelled to the hPrxII decameric structure	<b>151</b>
<b>4.33</b>	Cartoon diagram of the disulfide bond in the hPrxII-Trx model	<b>153</b>
<b>4.34</b>	Surface view of the hPrxII-Trx complex model	<b>154</b>
<b>5.1</b>	Chemical structure of cysteine and selenocysteine	<b>157</b>
<b>5.2</b>	The structure of the minimal SECIS	<b>158</b>
<b>5.3</b>	Overall cloning strategy for TrxR1	<b>160</b>
<b>5.4</b>	Agarose gel of <i>TrxR1</i> PCR	<b>164</b>
<b>5.5</b>	Elution profile from nickel affinity chromatography for TrxR1	<b>165</b>
<b>5.6</b>	Elution profile from gel filtration chromatography for native TrxR1	<b>166</b>
<b>5.7</b>	SDS-PAGE of TrxR1 from gel filtration chromatography	<b>167</b>
<b>5.8</b>	Graph of the DTNB activity assay for TrxR1	<b>168</b>

## List of Tables

<b>3.1</b>	Data processing statistics for the hPrxII(S-S)	<b>101</b>
<b>3.2</b>	The final X-ray refinement statistics for hPrxII(S-S) structure	<b>103</b>

## List of Equations

<b>1.1</b>	The formation of the superoxide anion	<b>24</b>
<b>1.2</b>	The formation of hydrogen peroxide from the superoxide anion	<b>24</b>
<b>1.3</b>	The Fenton reaction	<b>25</b>
<b>1.4</b>	The dismutation of H <sub>2</sub> O <sub>2</sub>	<b>26</b>
<b>1.5</b>	The oxidation of toxins in a coupled reduction with hydrogen peroxide	<b>26</b>
<b>1.6</b>	The conversion of hydroperoxides to alcohols	<b>26</b>
<b>1.7</b>	Deprotonation of a Cys residue to form the thiolate group	<b>28</b>
<b>1.8</b>	The oxidation reaction of a thiolate ion with H <sub>2</sub> O <sub>2</sub>	<b>29</b>
<b>1.9</b>	The reaction of the sulfenic acid with a thiol to form a disulfide	<b>29</b>
<b>1.10</b>	The hyper-oxidation reaction of the sulfenic acid with H <sub>2</sub> O <sub>2</sub>	<b>29</b>
<b>2.1</b>	Calculation of K <sub>av</sub>	<b>65</b>
<b>2.2</b>	Calculation of the log molecular weight	<b>65</b>
<b>2.3</b>	Beer-Lambert Law	<b>68</b>
<b>3.1</b>	Bragg's Law	<b>87</b>
<b>3.2</b>	The structure function equation	<b>89</b>
<b>3.3</b>	Calculation of electron density in a crystal	<b>89</b>
<b>3.4</b>	The electron density 2F <sub>o</sub> -F <sub>c</sub> map summation	<b>91</b>
<b>3.5</b>	The R factor equation	<b>91</b>
<b>5.1</b>	The activity of TrxR1	<b>163</b>